Biosimilars

Questions discussed in this category

With the increasing availability of biosimilars and their adoption onto payer formularies, how do you approach selection among available biosimilars in clinical practice?

Are there data or clinical experience that lead you to prefer certain biosimilars over others, particularly for adalimumab, rituximab, and infliximab?

1 Answer available

Biosimilars

Questions discussed in this category

Related Topics